The Department of Commerce uses the Defense Priorities & Allocations System (DPAS) to direct industrial resources to approved national defense, emergency preparedness, and energy programs, which can include health resources like cancer drugs when they are determined essential for national defense or emergency preparedness by authorizing agencies like the Department of Health and Human Services (HHS) or the Federal Emergency Management Agency (FEMA).
Under DPAS, companies are required to accept and prioritize these “rated” orders over unrated ones, ensuring a steady flow of critical materials throughout the supply chain.
How DPAS applies to cancer drug manufacturing:
Approved Program Determination:
For cancer drug manufacturing to fall under DPAS, it must be part of an approved program related to national defense, homeland security, or emergency preparedness.
For example, if a cancer drug is deemed essential for the health of the nation in a national emergency, the Department of Health and Human Services (HHS) or FEMA, as delegate agencies, could determine it as a critical national resource.
Priority Ratings:
If deemed necessary, federal agencies can issue a "rated order" to a manufacturer. This is a priority symbol, either "DO" or "DX," placed on contracts or orders.
Contractor Obligations:
Manufacturers receiving a rated order are required to give it preferential treatment, accepting it and prioritizing its fulfillment.
This means rescheduling other, non-rated orders to ensure timely delivery of materials and components for the rated cancer drug.
Supply Chain Impact:
The priority rating also "flows down" the supply chain. A manufacturer with a rated cancer drug order must place rated orders with their own suppliers and subcontractors to ensure they receive the necessary raw materials and components.
Special Priorities Assistance:
If companies encounter difficulties in meeting delivery schedules or need help locating suppliers for rated orders, they can request Special Priorities Assistance (SPA) from the Department of Commerce or other delegate agencies to resolve these issues.
___
LL's compiled 1600 data.
LL's compiled FDA Briefing.
LL/ICI have cured brain tumor(s)
5 years of No Evidence of Disease.
LL+Creativ-bio+ICI combo continue to deliver 1st in human history results.
Cytodyn non-disclosure of manufacturing to date, sure comes to mind.
Puzzle pieces to "Game Changer" ??.....
Under DPAS, companies are required to accept and prioritize these “rated” orders over unrated ones, ensuring a steady flow of critical materials throughout the supply chain.
How DPAS applies to cancer drug manufacturing:
Approved Program Determination:
For cancer drug manufacturing to fall under DPAS, it must be part of an approved program related to national defense, homeland security, or emergency preparedness.
For example, if a cancer drug is deemed essential for the health of the nation in a national emergency, the Department of Health and Human Services (HHS) or FEMA, as delegate agencies, could determine it as a critical national resource.
Priority Ratings:
If deemed necessary, federal agencies can issue a "rated order" to a manufacturer. This is a priority symbol, either "DO" or "DX," placed on contracts or orders.
Contractor Obligations:
Manufacturers receiving a rated order are required to give it preferential treatment, accepting it and prioritizing its fulfillment.
This means rescheduling other, non-rated orders to ensure timely delivery of materials and components for the rated cancer drug.
Supply Chain Impact:
The priority rating also "flows down" the supply chain. A manufacturer with a rated cancer drug order must place rated orders with their own suppliers and subcontractors to ensure they receive the necessary raw materials and components.
Special Priorities Assistance:
If companies encounter difficulties in meeting delivery schedules or need help locating suppliers for rated orders, they can request Special Priorities Assistance (SPA) from the Department of Commerce or other delegate agencies to resolve these issues.
___
LL's compiled 1600 data.
LL's compiled FDA Briefing.
LL/ICI have cured brain tumor(s)
5 years of No Evidence of Disease.
LL+Creativ-bio+ICI combo continue to deliver 1st in human history results.
Cytodyn non-disclosure of manufacturing to date, sure comes to mind.
Puzzle pieces to "Game Changer" ??.....
2
